ADC Therapeutics SA - ADCT STOCK NEWS

ADC Therapeutics (NYSE: ADCT) has released its inaugural Environmental, Social, and Governance (ESG) report, showcasing its dedication to patient care and sustainable innovation. This report serves as a benchmark for future progress and reflects the company's commitment to ethical business practices. Key highlights include a review of global ESG efforts, a focus on patient safety and support, and a commitment to enhancing human capital.

The report is available for review on the company's website.

ADC Therapeutics (NYSE: ADCT) is hosting a live webcast today from 9:00 to 11:00 a.m. EST, showcasing its ADC platform and solid tumor pipeline. The company celebrates the launch of ZYNLONTA® for DLBCL in the US, achieved within five years of initiating clinical development. CEO Chris Martin highlights the exploration of ADC technology in solid tumors like ovarian, breast, and prostate cancers. The webcast will cover ADC assets, including three clinical-stage programs and new developments targeting PSMA for advanced prostate cancer.

ADC Therapeutics (NYSE: ADCT) will have its CEO, Chris Martin, participate in a fireside chat at the virtual Guggenheim Oncology Conference on February 9, 2022, at 9:30 a.m. EST. The event will be accessible via a live webcast on the company's Investor Relations page, with a replay available for 30 days. ADC Therapeutics specializes in targeted antibody drug conjugates (ADCs) for cancer treatment, with products like ZYNLONTA® approved for certain lymphomas and ongoing trials for other therapies, demonstrating a commitment to advancing cancer treatment.

ADC Therapeutics (NYSE: ADCT), a biotechnology company focused on improving cancer treatment, will host a live webcast on February 8 from 9:00 to 11:00 a.m. ET. The event will showcase its antibody drug conjugate (ADC) platform and pipeline for solid tumors. CEO Chris Martin, Senior VP Patrick van Berkel, and CMO Joseph Camardo will present insights into the company's ADC technology and ongoing clinical trials, including ZYNLONTA® and Cami. The webcast will be available for replay for 30 days on the company's website.

ADC Therapeutics has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of ZYNLONTA® in Japan. The agreement includes a $30 million upfront payment, potential milestones up to $205 million, and royalties based on net sales. This partnership expands ADC Therapeutics' global footprint and addresses the unmet need for effective cancer therapies in Japan. ZYNLONTA, a CD19-targeted antibody drug conjugate, is already approved in the U.S. for specific lymphoma indications.

ADC Therapeutics (NYSE: ADCT), based in Lausanne, Switzerland, announced that CEO Chris Martin will speak at the Jefferies London Healthcare Conference on November 16 at 11:20 a.m. GMT. The session will be available via a live webcast on the company's website. ADC Therapeutics specializes in next-generation antibody drug conjugates for treating hematologic malignancies and solid tumors. Its FDA-approved product ZYNLONTA® is indicated for relapsed diffuse large B-cell lymphoma. The company is also developing additional ADC therapies.

ADC Therapeutics has announced that abstracts for ZYNLONTA^® and ADCT-602 will be presented at the 63rd American Society of Hematology Annual Meeting from December 11-14, 2021, in Atlanta, GA. The presentations will cover data on ZYNLONTA's efficacy as a single agent and in combination therapies for non-Hodgkin lymphomas. Key highlights include results from the LOTIS-3 Phase 2 study and the use of ZYNLONTA post-CAR-T therapy. The company aims to showcase promising anti-tumor activity and a favorable safety profile.

ADC Therapeutics reported third quarter 2021 net sales of $13.1 million for ZYNLONTA, marking its first full quarter of sales. The company secured a financing agreement with HealthCare Royalty for up to $325 million, bolstering its liquidity, which totaled $530.2 million in cash and cash equivalents. Significant R&D expenses of $36.8 million were reported as the company invests in expanding its clinical pipeline. Despite increasing sales and a comprehensive patient support program, net loss rose to $71.5 million, attributed to higher operational costs and share-based compensation expenses.

ADC Therapeutics has announced the validation of its Marketing Authorization Application (MAA) for ZYNLONTA by the European Medicines Agency (EMA). This pivotal application is supported by data from the LOTIS-2 trial, which demonstrated an overall response rate of 48.3% in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The FDA had previously granted accelerated approval for ZYNLONTA in 2021. This validation marks an essential step towards making ZYNLONTA available to European patients in need.